• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 20, 2014

View Archived Issues

Pharma: Clinic roundup

Eli Lilly and Co., of Indianapolis, said the randomized, double-blind, global phase III REVEL study of ramucirumab in combination with chemotherapy in second-line non-small-cell lung cancer (NSCLC) showed a statistically significant improvement in the primary endpoint of overall survival (OS) in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel. Read More

Other news to note

Active Biotech AB, of Lund, Sweden, said partner Teva Pharmaceutical Industries Ltd., of Jerusalem, decided not to proceed to the randomization stage of the planned Libretto trial for Laquinimod (nerventra), an oral immunomodulator, in the treatment of relapsing remitting multiple sclerosis (RRMS), as the current design is no longer aligned with the regulatory strategy. Read More

Clinic roundup

Omeros Corp., of Seattle, reported the first patient was dosed in a second phase II trial of OMS824, the company’s phosphodiesterase 10, or PDE10, inhibitor in development to treat schizophrenia, Huntington’s disease (HD) and other cognitive disorders. Read More

Stock Movers

Read More

Financings roundup

Covagen AG, of Zurich, Switzerland, said it added Baxter Ventures as an investor in its series B financing round, raising the total of CHF44.9 million (US$50.6 million). Read More

Earnings roundup

NPS Pharmaceuticals Inc., of Bedminster, N.J., reported net global product sales of $15.3 million for the fourth quarter of 2013 and $31.8 million for the full year, for Gattex (teduglutide [rDNA origin]), which was launched in the U.S. in February 2013 for the treatment of patients with adult short bowel syndrome who are dependent on parenteral support. Read More

RNAi still sizzling: Arrowhead seeks $104.2M for HBV drug

Signaling the RNAi space remains a hot ticket, Arrowhead Research Corp. priced an underwritten offering of 5.5 million shares of common stock at $18.95 apiece, seeking to raise $104.225 million. The Pasadena, Calif.-based company granted the underwriters a 30-day option to purchase up to an additional 825,000 shares, potentially increasing the deal size by $15.6 million. Read More

Drugmakers secure spot on test flight of supply chain pilot

The FDA has cleared 13 drugmakers for the test run of its Secure Supply Chain Pilot Program. Each company along for the ride will get expedited entry for up to five approved drugs or APIs imported into the U.S. over the next two years. Read More

Orphan drug firm Versartis joins IPO queue with $80M filing

Versartis Inc., which holds worldwide rights to the long-acting recombinant human growth hormone (rHGH) VRS-317, last year suggested it could potentially move the treatment for growth hormone deficiency (GHD) all the way to approval and marketing on its own. Read More

Chelsea: ‘ballpark’ price, second-quarter launch of Northera in NOH

With a launch expected in the second half of this year, Chelsea Therapeutics International Ltd. is firming up other plans for Northera (droxidopa), just approved by the FDA for neurogenic orthostatic hypotension (NOH), or a sudden drop in blood pressure when the patient stands up. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe